SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Tetraphase Pharmaceuticals, Inc. (NASDAQ – TTPH)

BALA CYNWYD, March 17, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Tetraphase Pharmaceuticals, Inc. (“TTPH” or the “Company”) (NASDAQ – TTPH) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the proposed acquisition of the Company by AcelRX Pharmaceuticals, Inc. (“ACRX”) (NASDAQ: ACRX). Under the terms of the agreement, Tetraphase shareholders will receive only 0.6303 shares of ACRX stock and one contingent value right (CVR) for each share of Tetraphase stock that they own.

The investigation concerns whether the Tetraphase Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether ACRX is underpaying for the Company. For example, the deal price is well off the stock’s 52-week high of $28.00 per share.

If you own shares of Tetraphase stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.